Compositions and methods of use thereof

Inventors

Baker, Shenda M. • Wiesmann, William P. • Townsend, Stacy Marie

Assignees

Synedgen Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12533375-B2

Patent

Publication Date

2026-01-27

Expiration Date


Abstract

Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.

Core Innovation

The patent relates to treating a subject suffering from a pulmonary disease or disorder by administering an inhaled nebulizer solution composition comprising water-soluble polyglucosamine derivatives, specifically poly(acetyl, arginyl) glucosamine (PAAG). The PAAG is defined by formula (I) with n being an integer between 20 and 6000 and with each R1 independently selected from hydrogen, acetyl, and the specified R1 substituent type, with at least 25% of R1 substituents being hydrogen, at least 1% being acetyl, and at least 2% being the specified substituent type.

The nebulizer solution composition further includes a neutral osmol agent and is configured for inhaled administration. The neutral osmol agent is selected from glycerol, sorbitol, mannitol, erythritol, and trehalose, and the osmolality of the composition is between 150 and 550 mOsmol/kg.

The described approach is intended to improve mucociliary transport or clearance, thereby treating the pulmonary disease or disorder. The disclosure also states mucolysis, reduction of mucus viscosity, elasticity, and adhesion, reduction and disruption of bacterial biofilms, and modulation of inflammatory cytokine responses stimulated by LPS or DNA.

Claims Coverage

Two independent claims are identified: one directed to a method for treating a subject with a pulmonary disease or disorder via administration of a specific nebulizer solution, and one directed to the nebulizer solution composition itself. Across both independent claims, there are three core inventive features.

Nebulizer treatment composition configured for inhaled administration

A method for treating a subject suffering from a pulmonary disease or disorder comprising administering an effective amount of a nebulizer solution composition configured for inhaled administration, wherein the composition improves mucociliary transport or clearance to treat the pulmonary disease or disorder, and wherein the nebulizer solution composition comprises a neutral osmol agent and PAAG.

PAAG defined by formula (I) with specified R1 substituent proportions

PAAG comprising formula (I) wherein n is an integer between 20 and 6000 and each R1 is independently selected from hydrogen, acetyl, and the specified R1 substituent type, wherein at least 25% of R1 substituents are hydrogen, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are the specified R1 substituent type.

Neutral osmol agent selected group with constrained osmolality

A neutral osmol agent selected from glycerol, sorbitol, mannitol, erythritol, and trehalose, wherein the osmolality of the composition is between 150-550 mOsmol/kg.

The independent claims are directed to both a method of treating pulmonary disease using inhaled nebulizer solution and to the nebulizer solution composition itself. In both cases, the key inventive elements are the defined PAAG structure/composition and the presence of a neutral osmol agent from a specified group, with the composition osmolality constrained to 150-550 mOsmol/kg.

Stated Advantages

Improves mucociliary transport or clearance.

Reduces and disrupts bacterial biofilms including MRSA, P. aeruginosa, and B. cepacia.

Reduces mucus/biofilm viscosity and improves mucociliary transport as assessed by muOCT imaging.

Potentiates and/or acts synergistically or additively with antibiotics, including vancomycin, tobramycin, aztreonam, and oxacillin.

Acts synergistically or additively with polyols such as sorbitol and xylitol.

Documented Applications

Treating a pulmonary disease or disorder using an inhaled nebulizer solution composition comprising PAAG and a neutral osmol agent.

Inhaled administration intended to improve mucociliary transport or clearance in the context of pulmonary disease or disorder.

Treating or preventing pulmonary and gastrointestinal disorders, including cystic fibrosis and related mucosal diseases such as DIOS/meconium ileus.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.